Nic brings decades of executive experience in the biotechnology sector. His leadership and expertise continue to drive innovation and progress in the biotechnology industry.
A native of Sweden, Nic’s career spans leadership roles at prominent biotech firms including his current role as president and CEO of Klondike Biopharma.
Prior to joining Klondike, Nic served as CEO of Trillium Therapeutics, which was later acquired by Pfizer. During his tenure, Nic orchestrated Trillium’s transformation from a discovery-based academic spin-out venture to a publicly listed, clinical-stage immuno-oncology company. Under his guidance, Trillium expanded from a team of one to 65 employees, raising over $200 million in funding.
Nic joined Trillium from YM BioSciences where held the roles of Executive Vice President and Chief Scientific Officer when the company completed its Initial Public Offering in 2002. Throughout his career, Nic has held various corporate, scientific and non-profit board positions, he currently is Chair of Strike Pharma and serves as a director at Vasomune Therapeutics.
Nic earned his PhD in immunology from the University of Toronto, where he also completed his postdoctoral training.
